A Non-Lipolysis Nanoemulsion Improved Oral Bioavailability by Reducing the First-Pass Metabolism of Raloxifene, and Related Absorption Mechanisms Being Studied

OBJECTIVE: A non-lipolysis nanoemulsion (NNE) was designed to reduce the first-pass metabolism of raloxifene (RAL) by intestinal UDP-glucuronosyltransferases (UGTs) for increasing the oral absorption of RAL, coupled with in vitro and in vivo studies. METHODS: In vitro stability of NNE was evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Jing-Yi, Chen, Zhong-Yun, Huang, Chuan-Li, Huang, Bei, Zheng, Yu-Rong, Zhang, Ying-Feng, Lu, Ban-Yi, He, Lin, Liu, Chang-Shun, Long, Xiao-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457831/
https://www.ncbi.nlm.nih.gov/pubmed/32922013
http://dx.doi.org/10.2147/IJN.S259993

Ejemplares similares

Ejemplares similares